I do not believe that Kevetrin will show much efficacy in this trial at a dose of 200 mg/sq m.
However, I am starting to believe that we may hear possibly about rather significant evidence of activity at the next higher dose cohort, at least I hope so.
To see the unreliability of HED, we only need to look at the first 4 cohorts for K and the appearance of p21 under 75 mg/m2 and probably at 50 mg/m2. In mouse studies p21 first shows up at 50 mg/kg, which would be 155 mg/m2 HED. So, p21 increases apparently appear in humans at 1/3 to 1/2 the dose equivalent of that in mice. That is one major form of misleading.